FOXO1/3: Potential suppressors of fibrosis

Ageing Res Rev. 2018 Jan:41:42-52. doi: 10.1016/j.arr.2017.11.002. Epub 2017 Nov 11.

Abstract

Fibrosis is a universally age-related disease that involves nearly all organs. It is typically initiated by organic injury and eventually results in organ failure. There are still few effective therapeutic strategy targets for fibrogenesis. Forkhead box proteins O1 and O3 (FOXO1/3) have been shown to have favorable inhibitory effects on fibroblast activation and subsequent extracellular matrix production and can ameliorate fibrosis levels in numerous organs, including the heart, liver, lung, and kidney; they are therefore promising targets for anti-fibrosis therapy. Moreover, we can develop appropriate strategies to make the best use of FOXO1/3's anti-fibrosis properties. The information reviewed here should be significant for understanding the roles of FOXO1/3 in fibrosis and should contribute to the design of further studies related to FOXO1/3 and the fibrotic response and shed light on a potential treatment for fibrosis.

Keywords: Aging; Extracellular matrix; FOXO1/3; Fibroblast; Fibrosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Extracellular Matrix / metabolism
  • Fibrosis / metabolism
  • Fibrosis / pathology
  • Fibrosis / prevention & control
  • Forkhead Box Protein O1 / metabolism*
  • Forkhead Box Protein O3 / metabolism*
  • Humans
  • Kidney / metabolism
  • Kidney / pathology
  • Liver Cirrhosis / metabolism*
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / prevention & control
  • Myocardium / metabolism
  • Myocardium / pathology
  • Pulmonary Fibrosis / metabolism*
  • Pulmonary Fibrosis / pathology
  • Pulmonary Fibrosis / prevention & control

Substances

  • FOXO1 protein, human
  • FOXO3 protein, human
  • Forkhead Box Protein O1
  • Forkhead Box Protein O3